RT Journal Article
T1 Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study.
A1 Espinosa, Enrique
A1 Soriano, Virtudes
A1 Malvehy, Josep
A1 Berrocal, Alfonso
A1 Martínez de Prado, Purificación
A1 Quindós, María
A1 Soria, Ainara
A1 Márquez-Rodas, Iván
A1 Palacio, Isabel
A1 Cerezuela, Pablo
A1 López-Vivanco, Guillermo
A1 Alonso, Lorenzo
A1 Samaniego, Elia
A1 Ballesteros, Ana
A1 Puértolas, Teresa
A1 Díaz-Beveridge, Rodrigo
A1 de la Cruz-Merino, Luis
A1 López Castro, Rafael
A1 López López, Rafael
A1 Stevinson, Kendall
A1 Del Barrio, Patricia
A1 Tornamira, Maria V
A1 Guillém, Vicente
A1 Martín-Algarra, Salvador
AB Adjuvant interferon-α2b (IFN-α2b) has been studied extensively in clinical trials, but there have been few studies of real-world use. The aim of this study is to describe the IFN-α2b real-world patterns in patients with high-risk melanoma in Spain. This was a retrospective and multicentre chart review study of an unselected cohort of patients with melanoma at high risk for relapse (stage IIB/IIC/III) treated with IFN-α2b. Patterns were assessed in terms of dose and compliance to planned treatment. A survival analysis was carried out for the full population and according to Kirkwood scheme compliance and the presence of ulceration. Of 327 patients treated with IFN-α2b, 318 received a high-dose regimen following the standard Kirkwood scheme; thus, patterns are described for this regimen. A total of 121 (38%) and 88 (28%) patients had at least one dose reduction during the induction and maintenance phases, respectively. Dose delay was required in fewer than 10% of patients. A total of 78, 40 and 38% of the patients completed the induction phase, maintenance phase and completed treatment, respectively. The median progression-free and overall survival for the full population were 3.2 and 10.5 years, respectively. There were no differences in progression-free survival and overall survival according to Kirkwood scheme compliance and the presence of ulceration. The most frequent adverse events were neutropenia (31%) and fatigue (30%). High-dose IFN-α2b is the most frequently used regimen in Spain as an adjuvant systemic treatment for high-risk melanoma. Despite poor compliance, in this retrospective study, IFN-α2b treatment provided a benefit consistent with that described previously.
YR 2016
FD 2016
LK http://hdl.handle.net/10668/9903
UL http://hdl.handle.net/10668/9903
LA en
DS RISalud
RD Apr 5, 2025